Sign In
Buy CLSD
$0.410
+0 (+0%)
At Close: Mar 13, 2026
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue Estimates
06:11pm, Wednesday, 10'th Mar 2021
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.69% and -98.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th
Earnings Preview: Clearside Biomedical, Inc. (CLSD) Q4 Earnings Expected to Decline
01:38pm, Wednesday, 03'rd Mar 2021
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Initial Safety Data from First Cohort Expected Mid-2021 -
Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021
07:05am, Wednesday, 24'th Feb 2021
ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021
07:05am, Tuesday, 23'rd Feb 2021
ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Circling Back On Clearside Biomedical
11:55am, Monday, 22'nd Feb 2021
For Clearside Biomedical, the onboarding of a new contract manufacturer should finally put its CRL issues for ocular therapy XIPERE in the rearview mirror. This move should pave the way for an NDA res
ALPHARETTA, Ga., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting
07:05am, Monday, 08'th Feb 2021
- Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders -
Clearside Biomedical's (CLSD) Shares March Higher, Can It Continue?
06:04am, Tuesday, 02'nd Feb 2021
As of late, it has definitely been a great time to be an investor in Clearside Biomedical (CLSD).
Implied Volatility Surging for Clearside Biomedical (CLSD) Stock Options
09:47am, Thursday, 14'th Jan 2021
Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.
Are You Looking for a Top Momentum Pick? Why Clearside Biomedical, Inc. (CLSD) is a Great Choice
12:47pm, Wednesday, 13'th Jan 2021
Does Clearside Biomedical, Inc. (CLSD) have what it takes to be a top stock pick for momentum investors? Let's find out.
ALPHARETTA, Ga., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering
07:05am, Wednesday, 06'th Jan 2021
ALPHARETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical: SCS Microinjector Platform With Significant Upside
02:01am, Tuesday, 05'th Jan 2021
Clearside Biomedical is aiming to make ocular gene therapy accessible. XIPERE NDA resubmission and potential approval in 2021 triggering a $15 million payment from partner Bausch Health.
Week 1 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge
04:28pm, Saturday, 02'nd Jan 2021
Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year with avg a
